Attached files
file | filename |
---|---|
EX-99.1 - PRESENTATION - Cellular Biomedicine Group, Inc. | cbmg_ex991.htm |
8-K - CURRENT REPORT - Cellular Biomedicine Group, Inc. | cbmg-20201231.htm |
Exhibit 99.2
Cellular Biomedicine Group Announces Data to be Presented at 2020
ASH Annual Meeting
●
C-CAR088 Anti-BCMA CAR-T Cell Therapy for Multiple Myeloma
(MM)
●
C-CAR039 Novel Anti-CD19/CD20 Bi-Specific CAR-T Cell Therapy for
Relapsed/Refractory (r/r) B-Cell NHL
●
C-CAR066
CAR-T Cell Therapy for B-Cell NHL Patients Who Are
Relapsed/Resistant Following CD19 CAR-T Therapy
GAITHERSBURG,
MD and SHANGHAI, China, December 4, 2020 – Cellular
Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or
the “Company”), a biopharmaceutical firm engaged in the
drug development of immunotherapies for cancer and stem cell
therapies for degenerative diseases, announced today that three
abstracts relating to its immuno-oncology drug development have
been accepted for presentation at the
62nd
American Society of Hematology (ASH)
Annual Meeting and Exposition to be held as a virtual event on
December 5-8, 2020.
C-CAR088
Abstract
Title: An Anti-BCMA CAR T-Cell Therapy (C-CAR088) Shows
Promising Safety and Efficacy Profile in Relapsed or Refractory
Multiple Myeloma
Program: Oral
and Poster Abstracts
Type: Oral
Session: 653.
Myeloma/Amyloidosis: Therapy, excluding Transplantation: Novel
Therapies Targeting B Cell Maturation Antigen in
Relapsed/Refractory Multiple Myeloma
Date: Saturday,
December 5, 2020
Time: 1:15pm
PST
Abstract
Online:
https://ash.confex.com/ash/2020/webprogram/Paper138734.html
A copy of the presentation materials will be made available on the
Investor Relations section of the Company website following the
presentation.
C-CAR039
Abstract Title: Developing a Novel Anti-CD19/CD20 Bi-Specific
Chimeric Antigen Receptor T (CAR-T) Cell Therapy for
Relapsed/Refractory (r/r) B-Cell NHL
Online only:
https://ashpublications.org/blood/article/136/Supplement%201/8/473629/Developing-a-Novel-Anti-CD19-CD20-Bi-Specific
C-CAR066
Abstract Title: Early Clinical Results of a Novel Anti-CD20
Chimeric Antigen Receptor (CAR)-T Cell Therapy for B-Cell NHL
Patients Who Are Relapsed/Resistant Following CD19 CAR-T
Therapy
Online only: https://ashpublications.org/blood/article/136/Supplement%201/8/473636/Early-Clinical-Results-of-a-Novel-Anti-CD20
About Cellular Biomedicine Group, Inc.
Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) develops
proprietary cell therapies for the treatment of cancer and
degenerative diseases. The company conducts immuno-oncology and
stem cell clinical trials in China using products from its
integrated GMP laboratory. The Company’s GMP facilities in
China, consisting of twelve independent cell production lines, are
designed and managed according to both China and U.S. GMP
standards. Its Shanghai facility includes a “Joint Laboratory
of Cell Therapy” with GE Healthcare and a “Joint Cell
Therapy Technology Innovation and Application Center” with
Thermo Fisher Scientific. These partnerships focus on improving
manufacturing processes for cell therapies. CBMG currently has
ongoing CAR-T Phase I clinical trials in China. The China NMPA
(formerly CFDA) approved the Company’s IND application for a
Phase II trial for AlloJoin®, CBMG’s
“Off-the-Shelf” allogenic haMPC therapy for the
treatment of Knee Osteoarthritis (KOA), and has accepted the
Company’s IND application for a Phase II trial for
ReJoin® autologous haMPC therapy for the treatment of KOA. The
NMPA has also accepted CBMG’s dossier for an IND application
for clinical trials of anti-BCMA CAR-T. CBMG is included in the
broad-market Russell 3000® Index the small-cap Russell
2000® Index and the Loncar China BioPharma index. To learn
more about CBMG, please
visit www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities, investments, and other statements that
are not descriptions of historical facts, including our
expectations regarding our immuno-oncology and regenerative
medicine clinical trials, including trials of our CAR-T Cell
therapies, may be forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include any risks
detailed from time to time in CBMG’s reports filed with the
Securities and Exchange Commission, Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K,
including risks regarding our ability to execute on proposed new
products, services or development thereof, the results of our
clinical research and development, particularly as they relate to
CAR-T Cell therapies, regulatory infrastructure governing cell
therapy and cellular biopharmaceuticals, our ability to enter into
agreements with any necessary manufacturing, marketing and/or
distribution partners for purposes of commercialization, our
ability to seek intellectual property rights for our product
candidates, uncertainty regarding competition in the industry in
which we operate, overall market conditions, and the impact of the
COVID-19 pandemic on our operations, including risks associated
with the evolving COVID-19 pandemic and actions taken in response
to it. Generally, forward-looking statements may be identified by
terms such as “may,” “will,”
“expects,” “plans,” “intends,”
“estimates,” “potential,”
“promising,” or “continue” or similar terms
or the negative of these terms. These statements reflect
CBMG’s current views with respect to future events or to its
future activities and involve known and unknown risks,
uncertainties and other factors which may cause CBMG’s actual
activities, actions or achievements to be materially different from
any future activities, actions or achievements expressed or implied
by the forward-looking statements. Given these uncertainties, you
should not place undue reliance on these forward-looking
statements. CBMG does not have any obligation to update these
forward-looking statements other than as required by
law.
Company/Investor Contact:
Sarah
Kelly
Director
of Corporate Communications, CBMG
Phone:
(301) 825-5320
Email:
sarah.kelly@cellbiomedgroup.com